Table 3.
The impact of VTE prophylaxis on the incidence of VTE in all hospitalized cirrhotic patients and subgroups of hospitalized cirrhotic patients
| DVT prophylaxis | VTE 6 | No VTE 220 | OR(95%CI) | P value |
|---|---|---|---|---|
| All Patients | ||||
| Pharmacologic | 1/6 (16.7%) | 26/220 (11.8%) | 1.49 (0.16-13.2) | 0.54 |
| Mechanical | 2/6 (33.3%) | 25/220 (11.9%) | 3.9 (0.68-22.4) | 0.15 |
| None | 3/6 (50%) | 169/220 (78%) | 0.28 (0.08-1.6) | 0.13 |
| Patients admitted with infections | ||||
| Pharmacologic | 1/2 (50%) | 15/119(12.6%) | 6.9 (0.41-116) | 0.25 |
| Mechanical | 0/2(0%) | 15/119 (12.6) | 0.98 (0.96-100) | 0.76 |
| None | 1/2 (50%) | 89/119(74.8%) | 0.31 (0.19-5.1) | 0.42 |
| Patients admitted with Bleeding | ||||
| Pharmacologic | 0/2(0%) | 7/52 (13.5%) | 0.96(0.9-1.02) | 0.76 |
| Mechanical | 2/2(100%) | 4/52 (7.71) | 1.5 (0.85-2.6) | 0.01 |
| None | 0/2(0%) | 41/52(7.8-8.8%) | NA | 0.06 |
| Patients with HCC | ||||
| Pharmacologic | 0/1(0%) | 11/101 (10.9) | NA | 0.89 |
| Mechanical | 1/1(100%) | 8/101(7.9%) | 1.1 (2.9-1.4) | 0.09 |
| None | 0/1(0%) | 82/101(81%) | NA | 0.19 |
| Patients with INR ≥ 1.8 | ||||
| Pharmacologic | 0/1(0%) | 0/1(0%) | 0.98(0.93-1..03) | 0.95 |
| Mechanical | 1/1 (100%) | 7/40 (17.5%) | 1.14(0.88-1.149) | 0.19 |
| None | 0/1(0%) | 31/40(77%) | 0.89(0.7-1.12) | 0.2 |
HCC: Hepatocellular carcinoma
INR: international normalized ratio